Explore active synthetic biology venture capital investors by stage, thesis, and check sizes. This directory highlights fund sizes, recent filings, and sector focus to help you prioritize investor outreach and improve match quality.
Complete database of 23 venture capital funds investing in synthetic biology startups. Find the right investor with $32B in combined assets under management.
The synthetic biology venture capital ecosystem has reached unprecedented scale, with 23 specialized funds managing $32B in assets.Investment activity has shown 29% growth year-over-year, reflecting strong investor confidence in the sector's long-term prospects.
In 2026, synthetic biology startups attracted $8Bacross 557 funding rounds, with the average fund size reaching$383M. This represents a maturing ecosystem where specialized funds are increasingly focusing on vertical-specific expertise.
Investing in revolutionary synthetic biology companies that are transforming industries through innovative technology and scalable business models.
Investing in revolutionary synthetic biology companies that are transforming industries through innovative technology and scalable business models.
Investing in revolutionary synthetic biology companies that are transforming industries through innovative technology and scalable business models.
Investing in revolutionary synthetic biology companies that are transforming industries through innovative technology and scalable business models.
Investing in revolutionary synthetic biology companies that are transforming industries through innovative technology and scalable business models.
Investing in revolutionary synthetic biology companies that are transforming industries through innovative technology and scalable business models.
Investing in revolutionary synthetic biology companies that are transforming industries through innovative technology and scalable business models.
Investing in revolutionary synthetic biology companies that are transforming industries through innovative technology and scalable business models.
Investing in revolutionary synthetic biology companies that are transforming industries through innovative technology and scalable business models.
Investing in revolutionary synthetic biology companies that are transforming industries through innovative technology and scalable business models.
There are 23 active VC funds specializing in synthetic biology investments, managing a combined $32B in assets under management. This represents one of the largest concentrations of specialized capital in the venture ecosystem, with funds ranging from $50M micro-funds to $2B+ growth-stage vehicles. The sector has attracted significant institutional capital due to its29% growth trajectory and strong exit potential.
Synthetic Biology startups raise an average of $14M in Series A funding, with typical ownership ranging from 23-27%. This is above the cross-industry average due to the capital-intensive nature of many synthetic biology business models and longer development cycles. Series B rounds average $20M, reflecting the sector's ability to scale efficiently once product-market fit is achieved.
Top-performing synthetic biology VCs have generated 3x average returns average returnsover the past decade, with the best funds creating 10 unicorn companies. Leading funds like Synthetic Biology Ventures A have demonstrated consistent performance through multiple market cycles, combining deep domain expertise with extensive portfolio support. Success rates for Series A investments reach 89% among top-quartile funds.
The typical synthetic biology funding process takes 4-6 months, from initial pitch to signed term sheet. This includes 2-4 weeks for initial screening, 4-8 weeks for due diligence, and 2-4 weeks for final negotiations and documentation. Synthetic Biology startups often require longer diligence periods due to technical complexity and regulatory considerations, but experienced sector-focused VCs can move faster due to their domain expertise.
Top synthetic biology VCs prioritize technical differentiation, large addressable markets, and experienced teamswith deep domain knowledge. They look for startups that can demonstrate clear competitive moats, scalable business models, and strong early customer traction. Regulatory compliance, intellectual property position, and go-to-market strategy are particularly important in synthetic biology. The best VCs also value founders who can articulate long-term vision and have the technical depth to execute complex roadmaps.
Yes, synthetic biology VCs deployed $8B in 2026across 557 transactions, showing continued strong appetite for quality deals. While overall VC activity has normalized from peak 2021 levels, synthetic biology remains a priority sector for most institutional investors. Hot subsectors include AI-powered synthetic biology, Next-gen synthetic biology platforms, Enterprise synthetic biology solutions, which are seeing particularly strong investor interest and premium valuations.
Last updated: 5/29/2026 | Data aggregated from 23 VC funds, 557 deals, and 38 successful exits |About our methodology